Semax

Each lot of Semax offered by Zynix Biolab is characterized for identity and purity prior to release:

• Purity: High-performance liquid chromatography (HPLC) verified to ≥99%.
• Identity: Confirmed by mass spectrometry (MS) against the expected molecular mass.
• Reference identifiers: CAS No. 80714-61-0; sequence Met-Glu-His-Phe-Pro-Gly-Pro; molecular formula reported in the literature as C₃₇H₅₁N₉O₁₀S (average mass ≈ 813.9). Lot-specific measured values are reported on the Certificate of Analysis (COA).
• Documentation: A lot-specific COA accompanies each unit; physical form is lyophilized powder.

These analyses constitute analytical characterizations of identity and purity only and do not imply any biological activity, efficacy, or fitness for any use. For research use only, not for human use.

A Certificate of Analysis is available per production lot, documenting HPLC purity and mass-spectrometry identity confirmation.

View Certificates of Analysis →

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

References to clinical phases/studies describe the compound in independent third-party literature (e.g., ClinicalTrials.gov, PubMed) and do not represent claims, testing, or approval by Zynix Biolab.

Semax is a synthetic heptapeptide structurally derived from the (4–10) fragment of adrenocorticotropic hormone (ACTH), comprising the ACTH(4–7) core extended at the C-terminus by the Pro-Gly-Pro (PGP) tripeptide, giving the sequence Met-Glu-His-Phe-Pro-Gly-Pro. In the scientific literature it has been characterized as a melanocortin-derived peptide that has been the subject of neurochemical and neurotrophic-signaling research.

Published third-party studies have investigated the compound’s reported modulation of the brain-derived neurotrophic factor (BDNF) / TrkB system in rodent hippocampal tissue, as well as its examined influence on dopaminergic and serotonergic markers and on neurotrophin gene transcription in cerebral ischemia models. The PGP fragment has additionally been studied as a structural element that has been reported to slow enzymatic degradation in vitro.

In terms of third-party research and regulatory history outside the United States, the compound has been described in the published literature as having been registered and used as a pharmaceutical in the Russian Federation (e.g., reported on Russia’s roster of vital and essential medicines), and Russian investigator-led clinical studies of the compound in cerebrovascular contexts have been reported in PubMed-indexed journals. No FDA- or EMA-registered clinical program for this compound was identified at the time of writing, and no corresponding ClinicalTrials.gov registration was confirmed. These third-party records describe the compound itself within independent science and regulatory systems and do not represent testing, registration, or approval by Zynix Biolab. For research use only, not for human use.

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

In the published third-party literature, Semax has been examined across several in-vitro and laboratory research lines, including:

• Studies of melanocortin / ACTH-fragment peptide chemistry and structure–stability relationships, including the role of the C-terminal Pro-Gly-Pro motif in enzymatic degradation assays.
• Investigations of the BDNF/TrkB neurotrophic signaling axis and of neurotrophin and receptor gene expression in rodent brain tissue and cerebral-ischemia models.
• Characterization of effects on dopaminergic and serotonergic neurochemical markers and on intracellular calcium dynamics in neuronal preparations.

These are areas of investigation appropriate to a controlled laboratory setting using validated assays and proper controls. The applications above are provided for scientific context only and describe published third-party research; they are not for human use, diagnostic use, or therapeutic use.

General laboratory handling guidance for the lyophilized research material:

• Storage: Store lyophilized powder at -20°C, protected from light and moisture; minimize freeze–thaw cycles. Refer to the lot COA for any lot-specific guidance.
• Reconstitution (bench preparation): For laboratory preparation, the lyophilized peptide may be reconstituted with bacteriostatic water or another suitable research-grade solvent, with the working concentration determined by the experimental protocol. Reconstituted aliquots are typically held refrigerated or frozen per laboratory practice.
• PPE / safety: Handle in a controlled laboratory environment using appropriate personal protective equipment (gloves, eye protection, lab coat) and standard laboratory safety practices.

This information describes laboratory handling of a research material and is not a dosing or administration instruction. For research use only — not for human use.

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

Selected peer-reviewed, third-party literature on the compound:

• Dolotov OV, et al. “Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.” Brain Research. 2006;1117(1):54–60. PMID: 16996037. PubMed
• Eremin KO, et al. “Semax, an ACTH(4–10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochemical Research. 2005;30(12):1493–1500. PMID: 16362768. PubMed
• Medvedeva EV, et al. “Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemia.” PubMed Central (PMC11498467)

These references are provided for scientific context only and are not claims by Zynix Biolab.